When treating cancer, there are choices to be made. Is surgery warranted? What is the role of chemotherapy? Radiation? How should these treatments be best combined? And today, CyberKnife® must be considered as an alternative treatment... or even as a primary treatment for certain types of tumors and patients.
Since 1998, more than 70,000 patients all over the world have been treated with the Cyberknife stereotactic radiosurgery system. Since that time, it has become the most reliable, trusted modality for intracranial radiosurgery treatment and the leading modality for radiosurgery of extracranial tumors. Today, there are over 70,000 patients treated and over 165 Cyberknife locations worldwide. CyberKnife is FDA-approved and reimbursable by Medicare and most insurance carriers. So, the question isn’t whether or not CyberKnife should be considered as an alternative – or even primary – treatment for solid-mass tumors throughout the body. The question is:
Where do you send your patients for the most informed radiosurgical care and the most precise, effective CyberKnife treatment?